DNM1L and rheumatoid arthritis: The use of DNM1L inhibitor, mdivi-1, downregulated the AKT/IKK pathway to attenuate NF-κB activation in RA-FLS, inflammatory cytokines, and ROS production, which in turn attenuated the inflammatory response in CIA mice.